43,518 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Acquired by TCG Advisory Services LLC

TCG Advisory Services LLC purchased a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 43,518 shares of the company's stock, valued at approximately $24,155,000. IDEXX Laboratories comprises approximately 1.6% of TCG Advisory Services LLC's portfolio, making the stock its 9th largest position. TCG Advisory Services LLC owned 0.05% of IDEXX Laboratories as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the company. Sapient Capital LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth $18,842,000. Axxcess Wealth Management LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at $2,090,000. Malaga Cove Capital LLC lifted its stake in shares of IDEXX Laboratories by 36.7% in the 4th quarter. Malaga Cove Capital LLC now owns 928 shares of the company's stock valued at $515,000 after purchasing an additional 249 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its stake in shares of IDEXX Laboratories by 58.1% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,621 shares of the company's stock valued at $900,000 after purchasing an additional 596 shares during the last quarter. Finally, Los Angeles Capital Management LLC lifted its stake in shares of IDEXX Laboratories by 2.4% in the 4th quarter. Los Angeles Capital Management LLC now owns 6,918 shares of the company's stock valued at $3,840,000 after purchasing an additional 163 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently commented on IDXX. Piper Sandler lowered IDEXX Laboratories from an "overweight" rating to a "neutral" rating and set a $525.00 price target on the stock. in a research note on Tuesday, January 30th. JPMorgan Chase & Co. upped their price target on IDEXX Laboratories from $600.00 to $630.00 and gave the company an "overweight" rating in a research note on Tuesday, February 6th. William Blair reiterated an "outperform" rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. StockNews.com downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Thursday. Finally, Barclays cut their price objective on IDEXX Laboratories from $655.00 to $570.00 and set an "overweight" rating on the stock in a report on Thursday. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $580.88.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, SVP George Fennell sold 8,198 shares of the firm's stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the transaction, the senior vice president now owns 6,712 shares of the company's stock, valued at $3,851,815.44. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, SVP George Fennell sold 8,198 shares of the company's stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the sale, the senior vice president now owns 6,712 shares in the company, valued at approximately $3,851,815.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the firm's stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the transaction, the chief executive officer now directly owns 79,247 shares in the company, valued at $45,377,624.67. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 43,524 shares of company stock valued at $24,871,960. Corporate insiders own 2.11% of the company's stock.

IDEXX Laboratories Stock Up 1.0 %

Shares of IDXX stock traded up $4.78 during trading hours on Friday, reaching $480.60. 547,954 shares of the stock were exchanged, compared to its average volume of 509,434. The business's fifty day moving average is $523.29 and its two-hundred day moving average is $513.58. The firm has a market capitalization of $39.69 billion, a P/E ratio of 46.52, a P/E/G ratio of 3.78 and a beta of 1.27. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.17.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, beating analysts' consensus estimates of $2.12 by $0.20. The business had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The company's revenue was up 8.8% on a year-over-year basis. During the same period last year, the business earned $2.05 EPS. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 11.05 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.